Holland & Knight Advises Kashiv Biosciences in Sale of Specialty Pharmaceuticals Unit to Amneal Pharmaceuticals

NEW YORK (April 9, 2021) – Holland & Knight represented Kashiv Biosciences LLC, a fully integrated specialty biopharmaceutical company, in the $100 million sale of its subsidiary Kashiv Specialty Pharmaceuticals LLC (KSP) to Amneal Pharmaceuticals LLC, a wholly owned subsidiary of Amneal Pharmaceuticals, Inc. (NYSE:AMRX). The deal was announced in January; closing was announced on April 5.

KSP, headquartered in New Jersey, focuses on the development of complex generic pharmaceuticals, innovative drug delivery platforms and novel 505(b)(2) drugs.

Amneal, which is also based in New Jersey, is a fully-integrated pharmaceutical company focused on the development, manufacture and distribution of generic and specialty drug products. The company has manufacturing operations in North America, Asia and Europe.

Holland & Knight's representation of Kashiv was led by Partners Amy Leder and Charles Weiss. They were assisted by Partners John Dierking, Marc Druckman, Alan Schwartz and Victoria Zerjav, and Associates Anush Yegyazarian and Max Lubin.

More information about the transaction can be found here.